2Armitage J O, Vose J M , Linder J, et al. Clinical significance of im munophenotype in diffuse aggressive non-Hodgkin ' s lymphoma [ J ]. J Clin Oncol, 1989, 7 ( 12 ) : 1783- 1790.
3Coiffier B, Brousse N, Peuehmaur M, et al. Peripheral T- cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen [ J ] . Ann Oneol , 1990 , 1 (1) :45-50.
4Grogan T M , Fielder K, Rangel C, et al. Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes. [J].J Clin Pathol, 1985,83(3) :279-288.
5Rudiger T, Weisenburger D D, Anderson M , et al. Peripheral T-cell lymphoma (exclu ding anaplastic large-cell lympho- ma ) : results from the nonHodgkin ' s Lymphoma classification project [ J ]. Annals of Oncology, 2002, 13 (2) :140-149.
6Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation [ J ] . Leukemia, 2006 , 20 ( 9 ) : 1533- 1538.
7Bang S M, Kim Y K, Park Y H, et al. High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma. [ J ]. Lym Leuk Phoma, 2005,46(11):1599-1604
8Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained longterm survival for patients with adult T-cell leukemia/lymphoma[ J] . Leukemia ,2005 , 19(5 ) :829-834.
9Shipp M A. Prognostic factors in aggressive non-Hodgkin' s lymphoma : who has " high -risk " disease [ J ] . Blood , 1994 , 83(11) :1165-1173.
10Zidan J, Hussein O, Basher W, et al. Serum CA125: a tumor marker for monitoring response to treatment and followup in patients with non-Hodgkin ' s lymphoma [ J ]. Oneologist,2004,9(4) :417-421.
